Organisation paid for research Program year 2025 Source: CMS Open Payments

Case Western Reserve University

Neither a doctor nor a teaching hospital

Research payments

$2,208,515

147 payments

Through program year 2025, Case Western Reserve University is reported as receiving $2,208,515 in research payments, across 147 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $474,724 41
2024 Research $257,709 14
2023 Research $413,135 29
2022 Research $79,206 10
2021 Research $261,512 21
2020 Research $436,518 16
2019 Research $285,711 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $592,540 60 payments
  2. Eli Lilly and Company $414,092 16 payments
  3. Roche Diabetes Care, Inc. $196,619 3 payments
  4. Alcon Research LLC $185,266 2 payments
  5. Siemens Medical Solutions USA, Inc. $142,645 10 payments
  6. Merck Sharp & Dohme Corporation $121,851 3 payments
  7. F. Hoffmann-La Roche AG $95,000 1 payment
  8. Sanofi US Services Inc. $86,930 7 payments
  9. Straumann USA LLC $81,783 2 payments
  10. Shionogi Inc $78,000 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $368,086 9 payments
  2. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $288,365 23 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $241,640 27 payments
  4. Rd002313 $156,140 1 payment
  5. Mechanism of Action and Efficacy of Fixed Combination Latanoprost + Netarsudil in Cell Culture and Potential Disease Modifying Effect $142,016 1 payment
  6. AI Pathway Companion breast cancer investigation $125,600 1 payment
  7. STUDY NAME#Assessing novel combination -lactam- -lactamase inhibitors against MDR Escherichia coli and Klebsiella pneumoniae $104,467 1 payment
  8. Exploring Interactions Between Rg6080 and Class A, B and D Lactamases $95,000 1 payment
  9. IIS 10/22 Immediate vs standard loading of 4 unsplinted implants supporting a maxillary overdenture using the Novaloc retention system: A randomized controlled study. $81,783 2 payments
  10. Epidemiology of Diabetes Interventions and Complications $66,951 6 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $12,736 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record